Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Oncologist or gynecologist
Responsible for treating a minimum of ≥2-6 (depending on country) ABC/MBC patients who meet the eligibility criteria.
Agrees to participate in the study and complete the eCRFs within the data collection period.
Female
≥18 years old.
HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.
Received palbociclib plus letrozole/aromatase inhibitor or palbociclib plus fulvestrant in line with the licenced indication(s).
No prior or current enrolment in an interventional clinical trial for ABC/MBC.
Minimum of three months of follow up data since palbociclib with fulvestrant initiation, or minimum of six months of follow up data since palbociclib with letrozole/aromatase inhibitor initiation (core medical record review).
Minimum of three months of follow up data since palbociclib initiation (German interim medical record review only).
Inoperable or recurrent breast cancer (Japan only)
You may not be if
Qualified less than 2 years ago or more than 35 years ago
Participated in observational research for ABC/MBC in the last 3 months
Have not prescribed either palbociclib plus fulvestrant or palbociclib plus aromatase inhibitor in line with the licenced indication(s).
